Sulopenem Etzadroxil/Probenecid — Competitive Intelligence Brief

Sulopenem Etzadroxil/Probenecid (Sulopenem Etzadroxil/Probenecid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: carbapenem antibiotic. Area: Infectious Diseases.

phase 3 carbapenem antibiotic bacterial cell wall synthesis Infectious Diseases Small molecule

Target snapshot

Sulopenem Etzadroxil/Probenecid (Sulopenem Etzadroxil/Probenecid) — Iterum Therapeutics, International Limited. Sulopenem etzadroxil/probenecid is a combination antibiotic that works by inhibiting bacterial cell wall synthesis and reducing the reabsorption of the antibiotic in the kidneys.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulopenem Etzadroxil/Probenecid TARGET	Sulopenem Etzadroxil/Probenecid	Iterum Therapeutics, International Limited	phase 3	carbapenem antibiotic	bacterial cell wall synthesis
Zavicefta, Ceftazidime-Avibactam	zavicefta-ceftazidime-avibactam	Pfizer	marketed	Cephalosporin antibiotic and beta-lactamase inhibitor combination	Bacterial cell wall synthesis
Fosfomycin and imipenem	Fosfomycin and imipenem	Juan A. Arnaiz	marketed	Beta-lactam antibiotic combination	Bacterial cell wall synthesis (MurA enzyme and penicillin-binding proteins)
cefepime/AAI101 combination	cefepime/AAI101 combination	Allecra	phase 3	beta-lactam antibiotic	bacterial cell wall synthesis
Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol	Tuberculosis Research Centre, India	phase 3	Anti-tuberculosis combination therapy	Multiple: DNA gyrase (moxifloxacin), mycobacterial cell wall synthesis (isoniazid, ethambutol), RNA polymerase (rifampicin), bacterial metabolism (pyrazinamide)
Maintaining carbapenem therapy	Maintaining carbapenem therapy	Assistance Publique - Hôpitaux de Paris	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (carbapenem antibiotic class)

1. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
2. Iterum Therapeutics, International Limited · 1 drug in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. Neutec Ar-Ge San ve Tic A.Ş · 1 drug in this class
5. Pfizer · 1 drug in this class